# John Cullity

> John Cullity is an Australian-trained physician, life-sciences adviser, biotech founder and executive based in Princeton, New Jersey. After medical training in haematology-oncology, he added health economics and business training, worked at the World Health Organization, World Bank, Schering-Plough and Sanofi, and then moved into transactions at Torreya and BioSynergy Partners. His later work has crossed company creation, board leadership and operating roles, including co-founding HaemaLogiX, chairing Race Oncology, advising Convergent Therapeutics and serving as CEO of NanoRetinal.

- **Role:** Chief Executive Officer at NanoRetinal; Managing Director at BioSynergy Partners
- **Organizations:** NanoRetinal, BioSynergy Partners, HaemaLogiX, Convergent Therapeutics, Race Oncology, Torreya Partners, Sanofi-Aventis, Schering-Plough, A.T. Kearney, World Bank, World Health Organization
- **Nationality:** Australian
- **Education:** Bachelor of Medicine, Bachelor of Surgery (MBBS), University of Western Australia, Membership (MRCP), Royal College of Physicians, Master of Science in Health Policy, Planning and Financing / Health Economics, London School of Economics and Political Science, Master of Business Administration, The Wharton School, University of Pennsylvania
- **Known for:** Participated in more than 100 licensing and M&A transactions in life sciences, according to Race Oncology's 2020 appointment announcement., Led or supported buy-side pharmaceutical transactions in oncology and diabetes at Sanofi-Aventis., Co-founded HaemaLogiX and served the company as an executive and director for 12 years.

## Career timeline

- **1983-1988** — Studied medicine at the University of Western Australia, later undertaking advanced haematology-oncology training at QEII Medical Centre in Perth.
- **1994-1999** — Completed Royal College of Physicians examinations, a master's at the London School of Economics and an MBA at Wharton.
- **1990s** — Worked with the World Health Organization and the World Bank and consulted at A.T. Kearney.
- **2001-2003** — Served in health economics and strategic pricing at Schering-Plough.
- **2003-2010** — Held pricing and business-development roles at Sanofi-Aventis, including oncology and diabetes transactions.
- **2010-2017** — Worked as a principal at Torreya Partners in New York and established Torreya Insights for transactions advisory.
- **2013-present** — Founded and has led BioSynergy Partners, a life-sciences advisory firm.
- **2014-2026** — Co-founded HaemaLogiX, served on its board for 12 years and chaired the company from January 2024 until June 2026.
- **2018-2023** — Served on the Race Oncology board, including as non-executive and executive chair, before retiring as a director in August 2023.
- **2020s** — Held a chief business advisory role at Convergent Therapeutics during its early company-building period.
- **2025-present** — Publicly identified as CEO of NanoRetinal, where he is supporting development and manufacture of NAR-001.

## Achievements

- Participated in more than 100 licensing and M&A transactions in life sciences, according to Race Oncology's 2020 appointment announcement.
- Led or supported buy-side pharmaceutical transactions in oncology and diabetes at Sanofi-Aventis.
- Co-founded HaemaLogiX and served the company as an executive and director for 12 years.
- Chaired Race Oncology during a period when the company advanced renewed development of bisantrene.
- Established BioSynergy Partners after his work at Torreya Partners and Torreya Insights.
- As NanoRetinal CEO, entered a 2025 manufacturing partnership with GBI Biomanufacturing for NAR-001.

## Latest updates

- **2026-06** — Stepped down from the HaemaLogiX board after 12 years as the company prepared for a planned ASX listing.
- **2026-03** — Listed as a NanoRetinal-affiliated co-author on research reporting restoration of rod function in chromophore-deficient mice.
- **2025-09** — As NanoRetinal CEO, announced a development and manufacturing partnership with GBI Biomanufacturing for NAR-001.
- **2024-01** — Appointed chair of HaemaLogiX after serving on its board since the company's formation.

## Links

- Website: https://nanoretinal.com/
- LinkedIn: https://www.linkedin.com/in/johncullity

---

Profile page: https://yespress.io/john-cullity
Published by YesPress — https://yespress.io
Last updated: 2026-09-27